Clinical trial of Alzheimer's disease drug shows clear reductions in AD development

December 15, 2003

A new clinical trial has shown that a treatment for Alzheimer's disease slowed the progression of cognitive decline in a group of patients with moderate to severe symptoms. The findings of the trials into the effectiveness of the drug Clioquinol on the treatment of AD, carried out by UCL's Department of Psychiatry and Behavioural Sciences and Prana Biotechnology Limited, are set out in the new edition of the Archives of Neurology, published on Monday 15th December.

The study enrolled 36 patients who were assessed for indicators of cognitive performance such as memory, orientation, language, attention and reasoning. The results were assessed using a cognitive score on the Alzheimer's disease Assessment Scale, the so-called ADAS-cog score. The scores range from 0 to 70, with lower scores indicating a healthy adult. As dementia progresses, the score increases. Eighteen of the patients were assigned to placebo and 18 received Prana's Alzheimer's disease drug, PBT-1 (Clioquinol) (the first of Prana's metal protein attenuating compounds (MPACs) to be developed for Alzheimer's disease). PBT-1 is a chemical that binds zinc and copper, and has been shown to lower the levels of A and the associated toxicity in the brains of Transgenic mice used as a model of Alzheimer's Disease.

The more affected patients entering Prana's pilot clinical trial (i.e. those with higher ADAS-cog scores) showed an average change in score at 24 weeks of about 1.5 points on PBT-1 and about 8.9 on placebo, a difference of 7.4. Generally, untreated patients with mild to moderate disease could be expected to gain six to 12 points in their ADAS-cog score over 12 months. A panel convened by the Food and Drug Administration in the US deemed an improvement of four points would be clinically significant.

"The results of this trial have been very encouraging to a clinician," said Dr Ritchie of UCL who led the study, adding; "Our findings have led to the development by Prana Biotechnology of new, possibly more effective drugs which hit the same target as Clioquinol. UCL plans to be involved in further testing of the principal using Clioquinol in a larger, UK multi-centre study which is seeking public funding."

Dr Susanne Sorensen, Head of Research at the Alzheimer's Society says: "The Alzheimer's Society welcomes this research as the results indicate that there may be a novel use for this already existing drug in the treatment of Alzheimer's disease. The trial presented here is limited in its scale and the Alzheimer's Society believes it would be valuable to see a larger scale trial. The potential for new drugs that may interfere with or revert the progression of Alzheimer's disease gives hope to people with dementia and their carers. There are currently only limited and expensive treatment options available for Alzheimer's disease and none that revert the disease for more than a short period."

University College London

Related Cognitive Decline Articles from Brightsurf:

Actively speaking two languages protects against cognitive decline
According to a study led by Marco Calabria, a researcher of the Speech Production and Bilingualism research group and of the Cognitive NeuroLab at the UOC, the diagnosis of mild cognitive impairment in Alzheimer patients with a higher degree of bilingualism is delayed.

Metformin treatment linked to slowed cognitive decline
A six-year study of older Australians with type 2 diabetes has uncovered a link between metformin use, slower cognitive decline and lower dementia rates.

Examining association between sleep duration, cognitive decline
Researchers in this observational study investigated the association between the amount of sleep at night and cognitive decline among participants in two large studies on aging.

Lifestyle improvements may lessen cognitive decline
Results from a new study suggest that lifestyle changes may help to improve cognition in older adults experiencing cognitive decline that precedes dementia.

Baby boomers show concerning decline in cognitive functioning
In a reversal of trends, American baby boomers scored lower on a test of cognitive functioning than did members of previous generations, according to a new nationwide study.

Memory loss reversed or abated in those with cognitive decline
Affirmativ Health sought to determine whether a comprehensive and personalized program, designed to mitigate risk factors of Alzheimer's disease could improve cognitive and metabolic function in individuals experiencing cognitive decline.

Delirium may cause long term cognitive decline
A new meta-analysis of 24 observational studies from researchers at Columbia University Vagelos College of Physicians and Surgeons found that delirium may cause significant long-term cognitive decline.

Is delirium associated with long-term cognitive decline?
The results of 23 studies were combined to examine whether an episode of delirium is a risk factor for long-term cognitive decline.

Maintaining heart health may protect against cognitive decline
People with a higher risk of developing cardiovascular disease have increased cognitive decline, including an increase in typical markers of Alzheimer's disease, suggesting that monitoring and controlling for heart disease may be key to maintaining and improving cognitive health later in life, according to research published today in the Journal of the American College of Cardiology.

Hearing aids may delay cognitive decline, research finds
Wearing hearing aids may delay cognitive decline in older adults and improve brain function, according to promising new research.

Read More: Cognitive Decline News and Cognitive Decline Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to